Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment

Figure 3

Effects of docetaxel on growth of subcutaneous LuCaP 23.1. LuCaP 23.1 fragments were implanted SC and animals were treated with 20 mg/kg docetaxel or placebo. Tumor volume was measured twice a week and blood was drawn weekly for determination of serum PSA levels. Mean ± SEM is plotted.A. Tumor volume: Docetaxel administration significantly decreased tumor volume compared to that of the control group. B. Serum PSA levels: Docetaxel decreased PSA levels significantly compared to those in the control animals.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us